The FDA has awarded IVT-8086 the title of Treating Rare Pediatric Disease (RPD) of Osteosarcoma.

Osteosarcoma is a malignant primary bone tumor, mostly seen in adolescents, good in the lower part of the fissine, upper tibia, the rapid development of the disease, mainly surgical treatment, five-year survival rate is not high.
the effect of pure radiotherapy is not satisfied.
preoperative radiotherapy plus surgery can improve efficacy.
radiotherapy should use ultra-high pressure therapy machine, multi-field radiation, including the entire infected bone and swollen soft tissue.
biopharmaceutical company Innova Therapeutics announced today that the FDA has awarded IVT-8086 the title of Rare Pediatric Disease (RPD) for the treatment of osteosarcoma (OS).
IVT-8086 is a humanized monoclonal antibody (mAb) with a high affinity for new cancer targets (SFRP2, secretion-type curl-related protein 2).
IVT-8086 has shown antagonism SFRP2, thereby blocking the non-classical Wnt/Ca2 plus pathway, leading to a decrease in angiogenesty and cell migration in tumor cells and an increase in tumor apoptosis.
Robert Ryan, chief executive of Innova Therapeutics, said: "The recognition of rare paediatric diseases highlights the devastating and significant medical needs of osteosarcoma.
IVT-8086 is likely to be the first FDA-approved new treatment for osteosarcoma."
.